BioShin is a clinical stage biopharmaceutical company.
BioShin is a wholly owned subsidiary of Biohaven Pharmaceuticals, a public biotech company. BioShin is a clinical stage biopharmaceutical company focused on developing medicines. It has proven leadership from global industry and academic settings and a portfolio of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 28, 2020 | Series A | $60M | 5 | OrbiMed | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
OrbiMed | Yes | Series A |
Cormorant Asset Management | — | Series A |
HBM Healthcare Investments AG | — | Series A |
Surveyor Capital | — | Series A |
Suvretta Capital Management | — | Series A |